Several targeted drugs for AML treatment, including the fms-like tyrosine kinase 3 (FLT3) inhibitors, the mutant isocitrate dehydrogenase (mIDH) inhibitors and the B-cell lymphoma-2 (BCL-2) inhibitors, have been approved in recent years [4–7]. Here, FLT3 is linked to acute myeloid leukemia.